XOMA Corporation (XOMA) announced it has received an $8.1M milestone payment from Viracta Therapeutics (VIRX), related to Day One Biopharmaceuticals’ (DAWN) recent sale of its Priority Review Voucher, PRV, for $108 million to an undisclosed buyer. “OJEMDA offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma the only approved therapy studied in and approved specifically for pLGG driven by BRAF fusions,” stated Owen Hughes, Chief Executive Officer of XOMA. “With this milestone in hand, we have more than recouped our initial capital outlay. And importantly, we anticipate future royalties on OJEMDA will contribute to a growing portfolio of royalty receipts that will help us drive sustainable free cash flow generation over time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA:
- LadRx, ImmunityBio mutually agree to terminate Aldoxorubicin license
- Brookline upgrades Dare Bioscience to Buy on improved funding
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- Xoma reports Q1 EPS (86c), consensus (81c)
- Biotech Alert: Searches spiking for these stocks today